Replies to post #157112 on Biotech Values

[oc631]

Edit: Just to clarify the 62% SVR rate was in GT3 patients specifically.

[DewDiligence]

GILD—Although extending treatment from 12w to 16w clearly helped, the SVR gap between genotype-2 and genotype-3 remained as wide as ever in the FUSION study: 94% (16w) and 86% (12w) for genotype 2 vs. 62% (16w) and 30% (12w) for genotype-3. Thus, even with 16w of treatment, genotype-2 patients did 3,200 basis points better than genotype-3 patients.